Previous 10 | Next 10 |
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Harrow Health will participate in the ...
Harrow Health, Inc. (HROW) Q2 2021 Earnings Conference Call August 10, 2021 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Lad...
Fourth Consecutive Quarter of Record Results Highlights for Second Quarter 2021: Record revenues of $18.1 million, a 125% increase compared with $8.1 million for the prior-year period; Gross margin was 75.6%, compared with 60.2% for the prior-year period; GAAP oper...
Harrow Health (HROW) has entered into an agreement with Sintetica to acquire the marketing and supply rights in the U.S. and Canada for AMP-100, a patented ophthalmic surgical drug candidate.When approved, AMP-100 will provide ocular surface anesthesia during ophthalmic in...
New Drug Application Expected to Be Filed in Late 2021 Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, loc...
NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the mark...
NovaBay Pharmaceuticals (NBY) has partnered with Harrow Health company (HROW) ImprimisRx to promote prescription Avenova.Avenova is an antimicrobial lid and lash solution for the management of numerous chronic eye conditions.ImprimisRx's president John Saharek called ...
NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces it has partnered with ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, to pr...
NASHVILLE, Tenn., July 15, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) an ophthalmic-focused healthcare company, today announced that the United States Patent and Trademark Office issued two Patents, No. US 10,993,921, B2, dated May 4, 2021, and No. US 11,045,432 B...
Dividends can fund a wonderful retirement. Today, we look at two amazing benefits that only dividends can provide. It's time to consider a change to dividends. For further details see: Yes, You Can Retire On Dividends
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...